SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas Cybercab launch, reinforced by pedal-less vehicles being added to Texass robotaxi roster, is driving attention to TSLA. Traders are divided between optimism over robotaxi/FSD expansion and expectations of a short squeeze, and skepticism that the event is largely hype that could trigger a sell-the-news pullback.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of Vikings VK2735 maintenance-trial readout is driving attention, with traders focused on durable weight loss, efficacy, and tolerability as key validation for the obesity program. Bullish participants expect differentiated results to support a re-rating or potential partnership, while bearish traders question whether the data will exceed existing GLP-1 therapies and warn of sell-the-news pressure and dilution.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution announcement and payout, with traders celebrating the elevated income and discussing reinvestment strategies. The community is also debating whether the distribution is sustainable and noting that Nasdaq-linked volatility can support option premiums while limiting upside and pressuring the share price after the ex-dividend date.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers failure to include expected protections against wildfire-related claims has intensified concerns over Edison Internationals liability exposure, prompting analyst downgrades and a sharp selloff. Traders are divided between bears warning of prolonged legal, credit and dividend risk and bulls calling the decline an overreaction and buying the oversold dip.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

A broad Bitcoin-led crypto rally is driving attention to Coinbase as a high-beta proxy, with traders citing renewed momentum, a technical breakout, and potential short covering. Bullish participants expect the move to continue, while skeptics call it speculative and note that Coinbase has lagged Bitcoin and remains sensitive to interest-rate concerns.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

The dominant catalyst is uncertainty over Paramount Skydances proposed acquisition of Warner Bros. Discovery after Californias attorney general canceled settlement talks amid the multistate antitrust case. Traders remain divided between expectations of a negotiated resolution and concerns that prolonged litigation could delay or derail the merger, increasing downside risk for WBD holders.

Corvex, Inc. is an AI cloud computing company, which specializes in GPU-accelerated infrastructure for AI workloads. Its products include GPU Clusters, Confidential Computing, Inference as a Service and GPU Node. The firm offers solutions include AI model builders, enterprises, federal and sovereign solutions. The company was founded by Seth Mitchell Demsey, Jay Crystal on October 21, 2024 and is headquartered in Arlington, VA.

Corvex Inc.

Movano Inc

A multi-year agreement for Corvex to provide NVIDIA Blackwell GPU clusters to an AI company, alongside planned data-center expansion, is driving attention and repositioning MOVE around an AI-infrastructure story. Traders are split between bullish expectations for momentum and a low-float short squeeze and concerns about the discounted financing, dilution risk, execution, and sharp post-pump fades.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Attention is centered on Keeta Personals rollout of ACH and multicurrency payment features alongside its Visa Direct partnership, which traders view as a potential fiat-to-blockchain payments catalyst. The community is broadly bullish, though skeptics question whether Visa is using Keetas network and whether meaningful transaction volume will follow, with the ASK Group UAE tokenization venture adding longer-term context.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

A recent quarterly report showing minimal revenue growth and declining policies-in-force has focused attention on Roots stalled growth strategy. Bulls emphasize continued profitability, cash generation, and the share-buyback program, while bears argue that reduced marketing spending supported earnings at the expense of customer growth and leaves the stock vulnerable to further weakness.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Exchange-listing momentum and heightened volume around Seekers Solana Mobile ecosystem are driving attention, with traders highlighting new access on major platforms and the tokens airdrop, staking, and phone-related utility. Bullish FOMO and short-squeeze speculation dominate, although some traders warn that free airdropped supply, staking unlocks, and sharp reversals could make the move a pump-and-dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Unusual volatility and bursts of volume/options activity are driving attention, with traders speculating about short covering or a potential squeeze despite no confirmed company announcement. The debate centers on whether momentum can persist ahead of DM1/FSHD and sirolimus updates, while skeptics point to delayed milestones, softer Elevidys demand and continued range-bound trading.

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will...

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Equity

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.


KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics experienced a 34% revenue decline due to lower ELEVIDYS sales, incurred a $39 million litigation charge, and faces ongoing regulatory and commercial adoption risks for its product portfolio.

Sarepta Therapeutics achieved quarterly operating profitability, appointed a new CEO with extensive industry experience, and strengthened its financial position with a $197 million increase in cash and investment holdings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$21.03
Prev Close	$20.86
Open	$20.56
Dividend Yield	0.00%
50-Day Moving Average	$17.69
Beta	1.24
Avg. Volume	3.16M
PE Ratio	-7.20

52-Week High	$25.32
52-Week Low	$14.68
Market Capitalization	$2.2B
EPS (Annual)	-$7.13
Price to Book	1.44
Revenue Per Employee	$2.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info